Suzhou Zanrong Pharmaceutical Technology Co. Ltd.

Study Objectives Primary Study Objectives: ? To evaluate the safety and tolerability of oral ZN-F-6418 capsules as monotherapy in subjects with KRAS G12D-mutant advanced solid tumors; ? To explore the maximum tolerated dose (MTD) of oral ZN-F-6418 capsules as monotherapy in subjects with KRAS G12D-mutant advanced solid tumors, providing a basis for recommending dosage in subsequent clinical trials. Secondary Study Objectives: ? To evaluate the pharmacokinetic (PK) characteristics of oral ZN-F-6418 capsules as monotherapy in subjects with KRAS G12D-mutant advanced solid tumors; ? To preliminarily evaluate the antitumor efficacy of oral ZN-F-6418 capsules as monotherapy in subjects with KRAS G12D-mutant advanced solid tumors.

Ia Main purpose To evaluate the safety and tolerability of oral ZN-B-2262 monotherapy in patients with advanced solid tumors, explore the maximum tolerated dose (MTD) or maximum dose (MAD) of oral ZN-B-2262 monotherapy in patients with advanced solid tumors, and provide a basis for the recommended dose in subsequent clinical trials; Secondary purpose To evaluate the pharmacokinetic characteristics of ZN-B-2262 and its metabolites in patients with advanced solid tumors after oral administration of ZN-B-2262 tablets or suspension; To preliminarily evaluate the anti-tumor efficacy of oral ZN-B-2262 monotherapy in patients with advanced solid tumors; Exploratory purpose To conduct research on the identification of metabolites in humans as needed. Ib&Ic Main purpose To evaluate the safety and tolerability of oral ZN-B-2262 combined with radiotherapy in patients with locally advanced head and neck tumors who are newly diagnosed or recurrent and suitable for radiotherapy alone; To explore the maximum tolerated dose (MTD) of ZN-B-2262 combined with radiotherapy in patients with locally advanced head and neck tumors who are newly diagnosed or recurrent and suitable for radiotherapy alone, and to provide a basis for the recommended dosage in subsequent clinical trials; Secondary purpose To evaluate the pharmacokinetic characteristics of ZN-B-2262 and major metabolites (if any) in patients with locally advanced head and neck tumors who are newly diagnosed or recurrent and suitable for radiotherapy alone; To preliminarily evaluate the anti-tumor efficacy of ZN-B-2262 combined with radiotherapy in patients with locally advanced head and neck tumors who are newly diagnosed or recurrent and suitable for radiotherapy alone;